The Protein Kinase Cβ–Selective Inhibitor, Enzastaurin (LY317615.HCl), Suppresses Signaling through the AKT Pathway, Induces Apoptosis, and Suppresses Growth of Human Colon Cancer and Glioblastoma Xenografts

Activation of protein kinase Cbeta (PKCbeta) has been repeatedly implicated in tumor-induced angiogenesis. The PKCbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses angiogenesis and was advanced for clinical development based upon this antiangiogenic activity. Activation of PKCbeta has now also been implicated in tumor cell proliferation, apoptosis, and tumor invasiveness. Herein, we show that Enzastaurin has a direct effect on human tumor cells, inducing apoptosis and suppressing the proliferation of cultured tumor cells. Enzastaurin treatment also suppresses the phosphorylation of GSK3betaser9, ribosomal protein S6(S240/244), and AKT(Thr308). Oral dosing with Enzastaurin to yield plasma concentrations similar to those achieved in clinical trials significantly suppresses the growth of human glioblastoma and colon carcinoma xenografts. As in cultured tumor cells, Enzastaurin treatment suppresses the phosphorylation of GSK3beta in these xenograft tumor tissues. Enzastaurin treatment also suppresses GSK3beta phosphorylation to a similar extent in peripheral blood mononuclear cells (PBMCs) from these treated mice. These data show that Enzastaurin has a direct antitumor effect and that Enzastaurin treatment suppresses GSK3beta phosphorylation in both tumor tissue and in PBMCs, suggesting that GSK3beta phosphorylation may serve as a reliable pharmacodynamic marker for Enzastaurin activity. With previously published reports, these data support the notion that Enzastaurin suppresses tumor growth through multiple mechanisms: direct suppression of tumor cell proliferation and the induction of tumor cell death coupled to the indirect effect of suppressing tumor-induced angiogenesis.

[1]  J. Soh,et al.  PKC-η mediates glioblastoma cell proliferation through the Akt and mTOR signaling pathways , 2004, Oncogene.

[2]  D. Rawlings,et al.  Protein Kinase C βII Regulates Akt Phosphorylation on Ser-473 in a Cell Type- and Stimulus-specific Fashion*♦ , 2004, Journal of Biological Chemistry.

[3]  D. O’Rourke,et al.  Sp1 is involved in Akt-mediated induction of VEGF expression through an HIF-1-independent mechanism. , 2004, Molecular biology of the cell.

[4]  F. Agani,et al.  Vascular Endothelial Growth Factor Transcriptional Activation Is Mediated by Hypoxia-inducible Factor 1α, HDM2, and p70S6K1 in Response to Phosphatidylinositol 3-Kinase/AKT Signaling* , 2004, Journal of Biological Chemistry.

[5]  M. Simons,et al.  Regulation of protein kinase B/Akt activity and Ser473 phosphorylation by protein kinase Cα in endothelial cells , 2004 .

[6]  William R Sellers,et al.  The biology and clinical relevance of the PTEN tumor suppressor pathway. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  A. Fields,et al.  Protein Kinase C (PKC) βII Induces Cell Invasion through a Ras/Mek-, PKCι/Rac 1-dependent Signaling Pathway* , 2004, Journal of Biological Chemistry.

[8]  B. Teicher,et al.  LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice , 2004, Cancer Chemotherapy and Pharmacology.

[9]  M. Faul,et al.  Acyclic N-(Azacycloalkyl)bisindolylmaleimides: Isozyme Selective Inhibitors of PKCβ. , 2003 .

[10]  M. Teitell,et al.  PKC-β controls IκB kinase lipid raft recruitment and activation in response to BCR signaling , 2002, Nature Immunology.

[11]  G. Mills,et al.  Convergence of Multiple Signaling Cascades at Glycogen Synthase Kinase 3: Edg Receptor-Mediated Phosphorylation and Inactivation by Lysophosphatidic Acid through a Protein Kinase C-Dependent Intracellular Pathway , 2002, Molecular and Cellular Biology.

[12]  G. Schwartsmann,et al.  Targeting protein kinase C: new therapeutic opportunities against high-grade malignant gliomas? , 2002, The oncologist.

[13]  M. Jirousek,et al.  Protein kinase C inhibitors as novel anticancer drugs , 2001, Expert opinion on investigational drugs.

[14]  D. Fabbro,et al.  The phosphatidylinositide 3'-kinase/Akt survival pathway is a target for the anticancer and radiosensitizing agent PKC412, an inhibitor of protein kinase C. , 2001, Cancer research.

[15]  A. Fields,et al.  Elevated protein kinase C betaII is an early promotive event in colon carcinogenesis. , 2001, Cancer research.

[16]  D. Alessi,et al.  Further evidence that 3‐phosphoinositide‐dependent protein kinase‐1 (PDK1) is required for the stability and phosphorylation of protein kinase C (PKC) isoforms , 2000, FEBS letters.

[17]  R. Vessella,et al.  Increased AKT Activity Contributes to Prostate Cancer Progression by Dramatically Accelerating Prostate Tumor Growth and Diminishing p27Kip1 Expression* , 2000, The Journal of Biological Chemistry.

[18]  H. Yoshiji,et al.  Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis. , 1999, Cancer research.

[19]  A. Fields,et al.  Overexpression of Protein Kinase C βII Induces Colonic Hyperproliferation and Increased Sensitivity to Colon Carcinogenesis , 1999, The Journal of cell biology.

[20]  P. Cohen,et al.  Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B , 1995, Nature.

[21]  J. Woodgett,et al.  Differential regulation of glycogen synthase kinase-3 beta by protein kinase C isotypes. , 1992, The Journal of biological chemistry.

[22]  Y Nishizuka,et al.  Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters. , 1982, The Journal of biological chemistry.

[23]  A. Fields,et al.  Protein kinase C (PKC) betaII induces cell invasion through a Ras/Mek-, PKC iota/Rac 1-dependent signaling pathway. , 2004, The Journal of biological chemistry.

[24]  Todd,et al.  Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning , 2002, Nature Medicine.

[25]  Beverly A. Teicher,et al.  Antiangiogenic effects of a protein kinase Cβ-selective small molecule , 2001, Cancer Chemotherapy and Pharmacology.

[26]  A. De Benedetti,et al.  eIF4E expression in tumors: its possible role in progression of malignancies. , 1999, The international journal of biochemistry & cell biology.